Nicox (FRA:NXOA) YoY EBITDA Growth : -58.71% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Nicox YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Nicox's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was -58.71%.

Nicox's EBITDA per Share for the six months ended in Dec. 2024 was €-0.25.

Nicox YoY EBITDA Growth Historical Data

The historical data trend for Nicox's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox YoY EBITDA Growth Chart

Nicox Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

43.61

-1.67

14.32

-8.22

24.56

Nicox Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial															79.52	-43.03	-811.76	78.81	-58.71

Nicox YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Nicox's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-0.298	-	-0.395)	/	\| -0.395 \|
=	24.56 %

Nicox's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(-0.246	-	-0.155)	/	\| -0.155 \|
=	-58.71 %

Nicox YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Nicox's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

NICXF:USA 0RCQ:UK ALCOX:France

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines